-
Je něco špatně v tomto záznamu ?
The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy
K. Mori, VM. Schuettfort, S. Katayama, E. Laukhtina, B. Pradere, F. Quhal, R. Sari Motlagh, H. Mostafaei, NC. Grossmann, P. Rajwa, F. König, A. Aydh, F. Soria, M. Moschini, PI. Karakiewicz, Y. Lotan, D. Scherr, M. Haydter, P. Nyirady, JYC. Teoh,...
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- cystektomie metody MeSH
- karcinom z přechodných buněk * patologie MeSH
- lidé MeSH
- močový měchýř patologie MeSH
- nádory močového měchýře * patologie MeSH
- vaskulární endoteliální růstový faktor A MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: Elevated preoperative plasma levels of the angiogenesis-related marker VEGF have been associated with worse oncological outcomes in various malignancies. OBJECTIVE: To investigate the predictive/prognostic role of VEGF in patients with urothelial carcinoma of the bladder (UCB) treated with radical cystectomy (RC). DESIGN, SETTING, AND PARTICIPANTS: VEGF plasma levels were measured preoperatively in 1036 patients with UCB who underwent RC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The correlation between plasma VEGF levels and pathological and survival outcomes was assessed using logistic regression and Cox regression analyses. Discrimination was assessed using the concordance index (C index). The clinical net benefit was evaluated using decision curve analysis (DCA). RESULTS AND LIMITATIONS: Patients with higher pretreatment plasma VEGF levels had poorer recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) according to log-rank tests (all p < 0.001). Higher VEGF levels were not independently associated with higher risk of lymph node metastasis, ≥pT3 disease, or non-organ-confined disease (all p > 0.05). Preoperative plasma VEGF levels were independently associated with RFS, CSS, and OS in preoperative and postoperative multivariable models. However, in all cases the C index increased by <0.02 and there was no improvement in net benefit on DCA. A limitation is that none of the patients received current elements of standard of care such as neoadjuvant chemotherapy. CONCLUSIONS: Elevated plasma VEGF levels were associated with features of biologically and clinically aggressive disease such as worse survival outcomes among patients with UCB treated with RC. However, VEGF appears to have relatively limited incremental additive value in clinical use. Further study of VEGF for UCB prognostication is warranted before routine use in clinical algorithms. PATIENT SUMMARY: Currently available models for predicting outcomes in bladder cancer are less than optimal. A protein called vascular endothelial growth factor (VEGF), which is a marker of the formation of blood vessels (angiogenesis), may have a role in predicting survival outcomes in bladder cancer.
Cancer Prognostics and Health Outcomes Unit University of Montreal Health Centre Montreal Canada
Department of Pathology Medical University of Vienna Vienna Austria
Department of Surgery S H Ho Urology Centre The Chinese University of Hong Kong Hong Kong China
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology King Fahad Specialist Hospital Dammam Saudi Arabia
Department of Urology King Faisal Medical City Abha Saudi Arabia
Department of Urology Landesklinikum Wiener Neustadt Vienna Austria
Department of Urology Medical University of Silesia Zabrze Poland
Department of Urology Medical University of Vienna Vienna Austria
Department of Urology Semmelweis University Budapest Hungary
Department of Urology The Jikei University School of Medicine Tokyo Japan
Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany
Department of Urology University of Texas Southwestern Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Division of Urology Department of Surgical Sciences University of Studies of Torino Turin Italy
Institute for Urology and Reproductive Health Sechenov University Moscow Russia
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Klinik für Urologie Luzerner Kantonsspital Lucerne Switzerland
Research Center for Evidence Based Medicine Tabriz University of Medical Sciences Tabriz Iran
Research Division of Urology Department of Special Surgery The University of Jordan Amman Jordan
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22033359
- 003
- CZ-PrNML
- 005
- 20230131151845.0
- 007
- ta
- 008
- 230120s2022 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.euf.2021.08.006 $2 doi
- 035 __
- $a (PubMed)34454852
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Mori, Keiichiro $u Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
- 245 14
- $a The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy / $c K. Mori, VM. Schuettfort, S. Katayama, E. Laukhtina, B. Pradere, F. Quhal, R. Sari Motlagh, H. Mostafaei, NC. Grossmann, P. Rajwa, F. König, A. Aydh, F. Soria, M. Moschini, PI. Karakiewicz, Y. Lotan, D. Scherr, M. Haydter, P. Nyirady, JYC. Teoh, S. Egawa, E. Compérat, SF. Shariat
- 520 9_
- $a BACKGROUND: Elevated preoperative plasma levels of the angiogenesis-related marker VEGF have been associated with worse oncological outcomes in various malignancies. OBJECTIVE: To investigate the predictive/prognostic role of VEGF in patients with urothelial carcinoma of the bladder (UCB) treated with radical cystectomy (RC). DESIGN, SETTING, AND PARTICIPANTS: VEGF plasma levels were measured preoperatively in 1036 patients with UCB who underwent RC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The correlation between plasma VEGF levels and pathological and survival outcomes was assessed using logistic regression and Cox regression analyses. Discrimination was assessed using the concordance index (C index). The clinical net benefit was evaluated using decision curve analysis (DCA). RESULTS AND LIMITATIONS: Patients with higher pretreatment plasma VEGF levels had poorer recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) according to log-rank tests (all p < 0.001). Higher VEGF levels were not independently associated with higher risk of lymph node metastasis, ≥pT3 disease, or non-organ-confined disease (all p > 0.05). Preoperative plasma VEGF levels were independently associated with RFS, CSS, and OS in preoperative and postoperative multivariable models. However, in all cases the C index increased by <0.02 and there was no improvement in net benefit on DCA. A limitation is that none of the patients received current elements of standard of care such as neoadjuvant chemotherapy. CONCLUSIONS: Elevated plasma VEGF levels were associated with features of biologically and clinically aggressive disease such as worse survival outcomes among patients with UCB treated with RC. However, VEGF appears to have relatively limited incremental additive value in clinical use. Further study of VEGF for UCB prognostication is warranted before routine use in clinical algorithms. PATIENT SUMMARY: Currently available models for predicting outcomes in bladder cancer are less than optimal. A protein called vascular endothelial growth factor (VEGF), which is a marker of the formation of blood vessels (angiogenesis), may have a role in predicting survival outcomes in bladder cancer.
- 650 12
- $a karcinom z přechodných buněk $x patologie $7 D002295
- 650 _2
- $a cystektomie $x metody $7 D015653
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a močový měchýř $x patologie $7 D001743
- 650 12
- $a nádory močového měchýře $x patologie $7 D001749
- 650 _2
- $a vaskulární endoteliální růstový faktor A $7 D042461
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Schuettfort, Victor M $u Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Katayama, Satoshi $u Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
- 700 1_
- $a Laukhtina, Ekaterina $u Department of Urology, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
- 700 1_
- $a Pradere, Benjamin $u Department of Urology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Quhal, Fahad $u Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
- 700 1_
- $a Sari Motlagh, Reza $u Department of Urology, Medical University of Vienna, Vienna, Austria; Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- 700 1_
- $a Mostafaei, Hadi $u Department of Urology, Medical University of Vienna, Vienna, Austria; Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
- 700 1_
- $a Grossmann, Nico C $u Department of Urology, Medical University of Vienna, Vienna, Austria; Klinik für Urologie, Luzerner Kantonsspital, Lucerne, Switzerland
- 700 1_
- $a Rajwa, Pawel $u Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Medical University of Silesia, Zabrze, Poland
- 700 1_
- $a König, Frederik $u Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Aydh, Abdulmajeed $u Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, King Faisal Medical City, Abha, Saudi Arabia
- 700 1_
- $a Soria, Francesco $u Division of Urology, Department of Surgical Sciences, University of Studies of Torino, Turin, Italy
- 700 1_
- $a Moschini, Marco $u Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology and Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele University, Milan, Italy
- 700 1_
- $a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada
- 700 1_
- $a Lotan, Yair $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA
- 700 1_
- $a Scherr, Douglas $u Department of Urology, Weill Cornell Medical College, New York, NY, USA
- 700 1_
- $a Haydter, Martin $u Department of Urology, Landesklinikum Wiener Neustadt, Vienna, Austria
- 700 1_
- $a Nyirady, Peter $u Department of Urology, Semmelweis University, Budapest, Hungary
- 700 1_
- $a Teoh, Jeremy Y C $u Department of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China
- 700 1_
- $a Egawa, Shin $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
- 700 1_
- $a Compérat, Eva $u Department of Pathology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Department of Urology, University of Texas Southwestern, Dallas, TX, USA; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Research Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. Electronic address: shahrokh.shariat@meduniwien.ac.at
- 773 0_
- $w MED00193513 $t European urology focus $x 2405-4569 $g Roč. 8, č. 4 (2022), s. 972-979
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34454852 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131151840 $b ABA008
- 999 __
- $a ok $b bmc $g 1891892 $s 1184694
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 8 $c 4 $d 972-979 $e 20210826 $i 2405-4569 $m European urology focus $n Eur Urol Focus $x MED00193513
- LZP __
- $a Pubmed-20230120
